Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
158
-
Total 13F shares, excl. options
-
33.5M
-
Shares change
-
-558K
-
Total reported value, excl. options
-
$360M
-
Value change
-
-$4.58M
-
Put/Call ratio
-
0.55
-
Number of buys
-
76
-
Number of sells
-
-56
-
Price
-
$10.74
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q4 2022
180 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q4 2022.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 158 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 33.5M shares
of 54.8M outstanding shares and own 61.16% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.73M shares), VANGUARD GROUP INC (3.1M shares), Bain Capital Life Sciences Investors, LLC (2.7M shares), FARALLON CAPITAL MANAGEMENT LLC (2.07M shares), STATE STREET CORP (1.78M shares), DISCIPLINED GROWTH INVESTORS INC /MN (1.72M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (1.33M shares), Chescapmanager LLC (1.16M shares), DIMENSIONAL FUND ADVISORS LP (1.02M shares), and GEODE CAPITAL MANAGEMENT, LLC (857K shares).
This table shows the top 158 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.